Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT ‐1 Trial
Authors' conclusion
Once-weekly treatment with tirzepatide demonstrated significant reductions in body weight and prespecified cardiometabolic measures compared with placebo in Japanese adults with obesity or overweight.
Study context
- Population
- Japanese adults in SURMOUNT-1 with BMI ≥ 30 kg/m² or ≥ 27 kg/m² and ≥ 1 weight-related comorbidity
- Participants
- 102 adults
- Comparison
- Tirzepatide 5, 10 or 15 mg once weekly vs placebo, alongside lifestyle intervention
- Primary endpoint
- Coprimary: mean percent change in body weight and proportion achieving ≥ 5% body weight reduction
- Follow-up
- Week 72
Methodological detailsprespecified subpopulation analysis, placebo-controlled, once-weekly
- Prespecified subpopulation analysis
- Placebo-controlled
- Once-weekly
Primary result
As reported in the abstract
Percent change in body weight (least squares mean, SE)
Tirzepatide 5 mg
−12.0
least squares mean · SE 1.7% · %
Tirzepatide 10 mg
−22.4
least squares mean · SE 1.7% · %
Tirzepatide 15 mg
−22.1
least squares mean · SE 1.6% · %
Placebo
−0.3
least squares mean · SE 1.6% · %
Tirzepatide 5 mg vs Placebo: P < 0.001 · Tirzepatide 10 mg vs Placebo: P < 0.001 · Tirzepatide 15 mg vs Placebo: P < 0.001
- ≥ 5% weight reduction: Tirzepatide 5 mg
- 91.7%
- ≥ 5% weight reduction: Tirzepatide 10 mg
- 100%
- ≥ 5% weight reduction: Tirzepatide 15 mg
- 96.6%
- ≥ 5% weight reduction: Placebo
- 15.4%
Further findings
Cardiometabolic measures · week 72
- Significant improvements in cardiometabolic measures with tirzepatide vs placebo
Safety
- No new safety concerns were identified
Original publication
Efficacy and Safety of Tirzepatide in Japanese Participants With Obesity: A Subpopulation Analysis of the SURMOUNT ‐1 Trial. Obesity (Silver Spring). Published 30 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →